Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a rare disease which is characterized by the progressive increase of pulmonary arterial pressure. PAH can lead to right cardiac insufficiency and death. Conventional and other treatment modalities that target the physiopathological and etiopathological causes of the disease are currently being used. Selexipag is an oral selective prostacyclin receptor agonist which was developed to overcome the pathophysiological mechanisms that play role in the PAH.